

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI XDC CAYMAN INC.

藥明合聯生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2268)

POSITIVE PROFIT ALERT

This announcement is made by WuXi XDC Cayman Inc. (the “**Company**”, which together with its subsidiaries collectively as the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company wishes to inform the shareholders (the “**Shareholders**”) and the potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards (IFRS)) for the six months ended June 30, 2025, and other information currently available to the Board, the Group is expected to record the following financial results:

- (1) an increase of more than 60% in revenue;
- (2) an increase of more than 67% in adjusted net profit before interest income and expense¹; and
- (3) an increase of more than 50% in net profit,

as compared with those for the corresponding period in 2024.

¹ The Group defines “adjusted net profit before interest income and expense” as net profit (an IFRS measure) after elimination of interest income (including interest income from bank balances, short-term bank deposits and time deposits) and interest expense as a non-operating item. It is a non-IFRS measure intended to supplement to the Group’s interim results prepared in accordance with IFRS and is not intended to be considered in isolation or as a substitute for IFRS net profit of the Company.

The Company considers that such expected increase was primary attributable to the following factors:

- (1) sustained growth of downstream demand in antibody drug conjugate (ADC) and broader bioconjugate industry;
- (2) the Group's market leadership and strengths to capture a substantial share of the bioconjugate CRDMO market; and
- (3) rapid ramp-up of newly commissioned production lines, consistently high utilization rate of the Group's production facilities, and continuously improving operating efficiency.

The Company considers that presenting the adjusted net profit before interest income and expense would offer greater insight into the Group's core performance and help investors to better assess the Company's long-term sustainability and value-creation potential. The Company is still in the process of finalizing the interim results of the Group for the six months ended June 30, 2025. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2025, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit committee of the Board. Shareholders and potential investors of the Company should refer to the interim results announcement of the Group for the six months ended June 30, 2025, which is expected to be published on August 18, 2025.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi XDC Cayman Inc.
Dr. Jincal LI

Executive Director and Chief Executive Officer

Hong Kong, July 23, 2025

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Jincal LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Ms. Ming SHI and Dr. Jijie GU as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Kenneth Walton Hitchner III and Mr. Hao ZHOU as independent non-executive directors.

* For identification purpose only